ClinicalTrials.gg
CompletedNCT00353938Updated Jul 15, 2024Results posted

Study of 3,4-Methylenedioxymethamphetamine-assisted Psychotherapy in People With Posttraumatic Stress Disorder

A Phase 2 interventional study of 3,4-methylenedioxymethamphetamine (125 mg) and 3,4-methyelendioxymethamphetamine (25 mg) in Posttraumatic Stress Disorder, sponsored by Lykos Therapeutics. Completed at 1 site in Switzerland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-07-15.

Sponsored by Lykos Therapeutics (part of Resilient Pharmaceuticals) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
14
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 38 studies testing N-Methyl-3,4-methylenedioxyamphetamine in Stress Disorders, Post-Traumatic — 11 open to participants now, 12 under way, 1 of them phase 3. N-Methyl-3,4-methylenedioxyamphetamine · Stress Disorders, Post-Traumatic.

Enrollment
26th of 38
14 · median 25
Started
2006
the only one that year
Phase 2
28 of 38
10 open now
Registered
2nd of 38
by date
Lead sponsor
16 of 38
Lykos Therapeutics

Among the 38 studies testing N-Methyl-3,4-methylenedioxyamphetamine in Stress Disorders, Post-Traumatic, this one is the 26th largest by enrollment, is the only one that started in 2006, is one of 28 in phase 2, and was the 2nd registered.

Stress Disorders, Post-Traumatic

2,688 studies on the registry are indexed under Stress Disorders, Post-Traumatic; 606 are open to participants now.

Browse Stress Disorders, Post-Traumatic studies →

Open to participants now

11 of the 38 studies testing N-Methyl-3,4-methylenedioxyamphetamine in Stress Disorders, Post-Traumatic are open now, in 3 countries. Recruiting first, the newest first:

6 more — sign in →

By country, each count listing its studies:

All 11 open studies →

About N-Methyl-3,4-methylenedioxyamphetamine

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 417 Stress Disorders, Post-Traumatic studies recruiting now, 187 (45%) set no upper age limit and 204 (49%) stop at 75 or younger; 63 take children under 18; 89 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 38 studies testing N-Methyl-3,4-methylenedioxyamphetamine in Stress Disorders, Post-Traumatic, or all of them as a file.
02

Study summary

This study will examine MDMA-assisted psychotherapy in individuals aged 18 years or older diagnosed with PTSD, with PTSD symptoms not improving after trying at least one treatment. This objective of this study is to determine whether three eight-hour long sessions of MDMA-assisted psychotherapy, scheduled three to five weeks apart, can be safely administered to participants with PTSD, and whether combining a fully therapeutic dose of MDMA with psychotherapy, when compared with a low ("active placebo") dose of MDMA, will reduce PTSD symptoms. Participants will be randomly assigned to receive the full dose of MDMA (125 mg) or assigned to receive a low or "active placebo" dose of MDMA (25 mg) during each of three experimental sessions.

Read the detailed description

Posttraumatic stress disorder (PTSD) occurs after experiencing a traumatic event or events. PTSD is a public health problem that causes a great deal of suffering.

This study will examine MDMA-assisted psychotherapy in individuals aged 18 years or older diagnosed with PTSD, with PTSD symptoms not improving after trying at least one treatment. This objective of this study is to determine whether three eight-hour long sessions of MDMA-assisted psychotherapy, scheduled three to five weeks apart, can be safely administered to participants with PTSD, and whether combining a fully therapeutic dose of MDMA with psychotherapy, when compared with a low ("active placebo") dose of MDMA, will reduce PTSD symptoms. Participants will be randomly assigned to receive the full dose of MDMA (125 mg) or assigned to receive a low or "active placebo" dose of MDMA (25 mg) during each of three experimental sessions.

People who receive the low dose of MDMA have the opportunity to take part in a second "open label" study continuation, wherein the participants will undergo three MDMA-assisted sessions, with the participant and the researchers knowing that a full dose of MDMA is being administered. People who receive the full dose of MDMA, and any person who received low-dose MDMA and does not undergo the open-label study continuation will have PTSD symptoms measured six and twelve months after the third session. People who take part in the open label study continuation have their PTSD symptoms assessed six and 12 months after the third Phase II MDMA-assisted session.

03

Conditions studied

  • Posttraumatic Stress Disorder

Keywords

  • PTSD, MDMA, psychotherapy, Switzerland
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosed with posttraumatic stress disorder (PTSD).
  • PTSD still remains after one or more prior treatment, with treatment including psychotherapy (talk therapy) or drug therapy
  • May meet criteria for a mood disorder
  • Must be at least 18 years old
  • Must be able to stop taking psychiatric medication during the course of the study, from the start of the study to the follow-up two months after experimental session 3.
  • Must agree to follow all rules and instructions relating to the experimental session, including restrictions on food and substance (alcohol and drug) consumption.
  • Must be willing to stay overnight at the researcher's office after each experimental session until the non-drug session occurring the next morning.
  • Must be willing to be contacted by one of the researchers on a daily basis for a week after each experimental session.
  • Female participants of must have a negative pregnancy test and must agree to use an effective form of .
  • Participants must have sufficient proficiency in speaking the German language to participate in MDMA-assisted psychotherapy. Participants must be able to read documents in German.

Exclusion criteria

Exclusion Criteria:

  • Cannot have history of or current primary psychotic disorder or bipolar affective disorder-1.
  • Dissociative identity disorder, or an eating disorder with active purging or borderline personality disorder.
  • Evidence or history of significant hematological, endocrine, cerebrovascular, cardiovascular, coronary, pulmonary, renal, gastrointestinal, immunocompromising, or neurological disease, including seizure disorder. (People with hypothyroidism who are on adequate and stable thyroid replacement will not be excluded).
  • Uncontrolled hypertension, peripheral vascular disease, hepatic disease (with or without abnormal liver enzymes), or history of hyponatremia or hyperthermia.
  • Being pregnant or lactating (nursing), or not practicing an effective method of .
  • Weight of less than 50 or more than 105 kg.
  • Patients reporting prior use of "Ecstasy" more than 5 times or at any time within the previous 6 months.
  • People who would present a serious suicide risk or who are likely to require hospitalization during the course of the study.
  • People who need ongoing concomitant therapy with a psychotropic drug.
  • Meeting criteria for substance abuse or dependence for any substance save caffeine or nicotine in the past 60 days.
  • People who cannot give adequate consent.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
14 participants (actual)

Study arms

  • Experimental
    Full Dose MDMA-assisted therapy (125 mg)

    Three 8-hour sessions of MDMA-assisted therapy with 125 mg of MDMA, followed by a supplemental dose of 62.5 mg MDMA

    Drug: 3,4-methylenedioxymethamphetamine (125 mg) · Behavioral: Therapy

  • Active comparator
    Active Placebo MDMA-assisted therapy (25 mg)

    Three 8-hour sessions of MDMA-assisted therapy with 25 mg of MDMA, followed by a supplemental dose of 12.5 mg MDMA

    Drug: 3,4-methyelendioxymethamphetamine (25 mg) · Behavioral: Therapy

Interventions

  • Participants will receive an initial dose of 125 mg MDMA orally and, if investigator and participant deem appropriate, 2.5 hours later they will receive 62.5 mg MDMA orally.

    Also known as: MDMA

  • Participants will receive a 25 mg MDMA orally, and if investigator and participant agree, 2.5 hours later they will receive 12.5 mg MDMA orally.

    Also known as: MDMA

  • BehavioralTherapy

    Non-directive therapy performed by a team of two co-therapists

06

What researchers measure

Primary outcomes

  1. Change From Baseline to Primary Endpoint in Clinician Administered PTSD Scale for DSM-IV (CAPS-IV)

    The CAPS-IV is a structured clinical interview designed to assess the symptoms and severity of PTSD. The CAPS-IV provides a means to evaluate the frequency and intensity dimensions of each symptom, the impact of symptoms on the patient's social and occupational functioning, the overall severity of the symptom complex, global improvement since baseline, and the validity of the ratings obtained. Total severity scores range from 0 to 136, with higher scores indicating greater severity of PTSD symptoms.

    Time frame: Less than 4 weeks before first experimental session (Baseline) to 3 weeks post 3rd experimental session (Primary Endpoint)

Secondary outcomes

  1. Change From Baseline to Primary Endpoint in Posttraumatic Stress Diagnostic Scale (PDS)

    The Posstraumatic Stress Diagnostic Scale (PSD) is a 49-item self-report instrument to aid in the diagnosis of PTSD. Questions are asked about symptoms experienced and participants respond on a scale from 0 ("not at all or only one time") to 3 ("5 or more times a week/almost always"). Items are summed to create a total score that ranges from 0 to 51, with higher scores indicating more PTSD symptoms.

    Time frame: Less than 4 weeks before first experimental session (Baseline) to 3 weeks post 3rd experimental session (Primary Endpoint)

07

Results

Posted Sep 16, 2021

Participant flow

Participants were recruited by calling for referrals from psychiatric hospitals, trauma counseling centers, psychiatrists and psychotherapists in the German-speaking part of Switzerland.

Participant flow — Overall Study
MilestoneFull Dose MDMA-assisted Therapy (125 mg Stage 1)Active Placebo MDMA-assisted Therapy (25 mg Stage 1)Full Dose MDMA-assisted Therapy (125 mg Stage 2)Full or Larger Dose MDMA-assisted Therapy (125 or 150 mg Stage 3)
Started9500
Completed stage 20040
Completed stage 30003
Completed8500
Not completed1000

Outcome measures

PrimaryChange From Baseline to Primary Endpoint in Clinician Administered PTSD Scale for DSM-IV (CAPS-IV)

The CAPS-IV is a structured clinical interview designed to assess the symptoms and severity of PTSD. The CAPS-IV provides a means to evaluate the frequency and intensity dimensions of each symptom, the impact of symptoms on the patient's social and occupational functioning, the overall severity of the symptom complex, global improvement since baseline, and the validity of the ratings obtained. Total severity scores range from 0 to 136, with higher scores indicating greater severity of PTSD symptoms.

Time frame:
Less than 4 weeks before first experimental session (Baseline) to 3 weeks post 3rd experimental session (Primary Endpoint)
Reported as:
Mean · score on a scale
Change From Baseline to Primary Endpoint in Clinician Administered PTSD Scale for DSM-IV (CAPS-IV)
score on a scaleFull Dose MDMA-assisted Therapy (125 mg)Active Placebo MDMA-assisted Therapy (25 mg)
Change From Baseline to Primary Endpoint in Clinician Administered PTSD Scale for DSM-IV (CAPS-IV)-15.6 ± 18.13.3 ± 15.3
SecondaryChange From Baseline to Primary Endpoint in Posttraumatic Stress Diagnostic Scale (PDS)

The Posstraumatic Stress Diagnostic Scale (PSD) is a 49-item self-report instrument to aid in the diagnosis of PTSD. Questions are asked about symptoms experienced and participants respond on a scale from 0 ("not at all or only one time") to 3 ("5 or more times a week/almost always"). Items are summed to create a total score that ranges from 0 to 51, with higher scores indicating more PTSD symptoms.

Time frame:
Less than 4 weeks before first experimental session (Baseline) to 3 weeks post 3rd experimental session (Primary Endpoint)
Reported as:
Mean · score on a scale
Change From Baseline to Primary Endpoint in Posttraumatic Stress Diagnostic Scale (PDS)
score on a scaleFull Dose MDMA-assisted Therapy (125 mg)Active Placebo MDMA-assisted Therapy (25 mg)
Change From Baseline to Primary Endpoint in Posttraumatic Stress Diagnostic Scale (PDS)-8.6 ± 13.07.3 ± 6.2

Adverse events

Collected over From baseline to end of Stage 3 (approximately 1 year). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Full Dose MDMA-assisted Therapy (125 mg Stage 1)0/9 (0%)2/9 (22.2%)8/9 (88.9%)
Active Placebo MDMA-assisted Therapy (25 mg Stage 1)0/5 (0%)0/5 (0%)3/5 (60%)
Full Dose MDMA-assisted Therapy (125 mg Stage 2)0/4 (0%)0/4 (0%)2/4 (50%)
Full or Larger Dose MDMA-assisted Therapy (125 or 150 mg Stage 3)0/3 (0%)0/3 (0%)1/3 (33.3%)
Most frequent serious events
Most frequent serious events
EventFull Dose MDMA-assisted Therapy (125 mg Stage 1)Active Placebo MDMA-assisted Therapy (25 mg Stage 1)Full Dose MDMA-assisted Therapy (125 mg Stage 2)Full or Larger Dose MDMA-assisted Therapy (125 or 150 mg Stage 3)
Metasteses to central nervous systemNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/90/50/40/3
Suicidal behaviorPsychiatric disorders1/90/50/40/3
Most frequent other events
Showing 10 of 35
Most frequent other events
EventFull Dose MDMA-assisted Therapy (125 mg Stage 1)Active Placebo MDMA-assisted Therapy (25 mg Stage 1)Full Dose MDMA-assisted Therapy (125 mg Stage 2)Full or Larger Dose MDMA-assisted Therapy (125 or 150 mg Stage 3)
AnxietyPsychiatric disorders4/91/50/40/3
FatigueGeneral disorders1/92/51/41/3
Angina tonsillitusInfections and infestations0/90/50/41/3
HeadacheNervous system disorders1/91/51/40/3
InsomniaPsychiatric disorders2/91/51/40/3
Iron deficiency AnemiaMetabolism and nutrition disorders0/90/51/40/3
Muscle spasmsMusculoskeletal and connective tissue disorders0/90/51/40/3
Neck painMusculoskeletal and connective tissue disorders0/90/51/40/3
Urinary tract infectionInfections and infestations0/90/51/40/3
Depressed moodPsychiatric disorders2/90/50/40/3

Baseline characteristics

Age, Continuous
Age, Continuous(years)Full Dose MDMA-assisted Therapy (125 mg)Active Placebo MDMA-assisted Therapy (25 mg)Total
Mean42.1 ± 12.840.0 ± 6.241.4 ± 11.2
Sex: Female, Male
Sex: Female, Male(Participants)Full Dose MDMA-assisted Therapy (125 mg)Active Placebo MDMA-assisted Therapy (25 mg)Total
Female7310
Male112
Race and Ethnicity Not Collected
Race and Ethnicity Not Collected(Participants)Full Dose MDMA-assisted Therapy (125 mg)Active Placebo MDMA-assisted Therapy (25 mg)Total
Count of participants——0
Country of origin
Country of origin(Participants)Full Dose MDMA-assisted Therapy (125 mg)Active Placebo MDMA-assisted Therapy (25 mg)Total
Switzerland7411
France101
Work status
Work status(Participants)Full Dose MDMA-assisted Therapy (125 mg)Active Placebo MDMA-assisted Therapy (25 mg)Total
On disability415
Fit for limited employment213
Working full-time123
Retired101
Duration of PTSD
Duration of PTSD(years)Full Dose MDMA-assisted Therapy (125 mg)Active Placebo MDMA-assisted Therapy (25 mg)Total
Mean16.4 ± 10.922.3 ± 12.118.3 ± 12.0
Duration of prior therapy
Duration of prior therapy(months)Full Dose MDMA-assisted Therapy (125 mg)Active Placebo MDMA-assisted Therapy (25 mg)Total
Mean39.9 ± 73.3123 ± 60.685.8 ± 71.4
On medication for PTSD at enrollment
On medication for PTSD at enrollment(Participants)Full Dose MDMA-assisted Therapy (125 mg)Active Placebo MDMA-assisted Therapy (25 mg)Total
Yes426
No426
08

Study locations

1 site
  • Offices of Peter Oehen MD
    Biberist, Solothurn, Switzerland
09

References and documents

Publications

  • Oehen P, Traber R, Widmer V, Schnyder U. A randomized, controlled pilot study of MDMA (+/- 3,4-Methylenedioxymethamphetamine)-assisted psychotherapy for treatment of resistant, chronic Post-Traumatic Stress Disorder (PTSD). J Psychopharmacol. 2013 Jan;27(1):40-52. doi: 10.1177/0269881112464827. Epub 2012 Oct 31. PubMed 23118021 ↗
  • Jerome L, Feduccia AA, Wang JB, Hamilton S, Yazar-Klosinski B, Emerson A, Mithoefer MC, Doblin R. Long-term follow-up outcomes of MDMA-assisted psychotherapy for treatment of PTSD: a longitudinal pooled analysis of six phase 2 trials. Psychopharmacology (Berl). 2020 Aug;237(8):2485-2497. doi: 10.1007/s00213-020-05548-2. Epub 2020 Jun 4. PubMed 32500209 ↗
  • Feduccia AA, Jerome L, Yazar-Klosinski B, Emerson A, Mithoefer MC, Doblin R. Breakthrough for Trauma Treatment: Safety and Efficacy of MDMA-Assisted Psychotherapy Compared to Paroxetine and Sertraline. Front Psychiatry. 2019 Sep 12;10:650. doi: 10.3389/fpsyt.2019.00650. eCollection 2019. PubMed 31572236 ↗
  • Mithoefer MC, Feduccia AA, Jerome L, Mithoefer A, Wagner M, Walsh Z, Hamilton S, Yazar-Klosinski B, Emerson A, Doblin R. MDMA-assisted psychotherapy for treatment of PTSD: study design and rationale for phase 3 trials based on pooled analysis of six phase 2 randomized controlled trials. Psychopharmacology (Berl). 2019 Sep;236(9):2735-2745. doi: 10.1007/s00213-019-05249-5. Epub 2019 May 7. PubMed 31065731 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2006 to primary completion in Sep 2009, 35 months.

Results were first posted in Sep 2021, 12 years after primary completion. A results delay was requested in Jul 2011.

Of 31 industry-sponsored phase 2 interventional studies under Stress Disorders, Post-Traumatic, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 33. This study's 35 months is above that.

Counting every sponsor, half of 118 studies reached it within 38 months; a quarter within 23 and three quarters within 53.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 17, 2006
First posted
Jul 19, 2006
StartActual
Sep 13, 2006
Primary completionActual
Sep 2, 2009
CompletionActual
Jan 10, 2011
Results delay requested
Jul 31, 2011
Results first posted
Sep 16, 2021
Last update
Jul 15, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 15, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00353938
Lead sponsor
Lykos Therapeutics
Collaborators
Swiss Medical Society for Psycholytic Therapy
Responsible party
Sponsor
First posted
Jul 19, 2006
Start date
Sep 13, 2006
Primary completion
Sep 2, 2009
Completion
Jan 10, 2011
Results posted
Sep 16, 2021
Last update
Jul 15, 2024

Study contacts

Peter Oehen, MD
principal investigator · private practice, Biberist, Switzerland

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: N-Methyl-3,4-methylenedioxyamphetamine

Start the discussion